International regulators particularly from the EU, Japan and Australia are increasingly requesting absolute bioavailability data in Phase II and Phase III. Obtaining this data using the traditional cross-over clinical design can take up to a year and $1.5M to allow for IV toxicity evaluations, IV formulation development and GMP manufacture.
Xceleron’s IV tracer approach eliminates all of these hurdles by utilizing a planned Phase I study, delivering the data in just 3 additional months at a fraction of the cost of a traditional crossover approach.
Over 5 of the world’s top pharmaceutical companies have used Xceleron’s IVPK Services to generate absolute bioavailability data for their filing packages.
Xceleron is acquired by Pharmaron
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.